Ocular Therapeutix (OCUL) Misses Q2 EPS by 12c

Ocular Therapeutix (NASDAQ: OCUL) reported Q2 EPS of ($0.45), $0.12 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $459 thousand versus the consensus estimate of $400 thousand.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Lockheed Martin frontrunner for $3.5B Ultra Maritime deal, sources say - FT
• RBC Capital Upgrades GEA Group AG (G1A:GR) (GEAGY) to Outperform